The stock of Tscan Therapeutics Inc (TCRX) has seen a -1.11% decrease in the past week, with a 4.69% gain in the past month, and a 22.85% flourish in the past quarter. The volatility ratio for the week is 6.98%, and the volatility levels for the past 30 days are at 7.43% for TCRX. The simple moving average for the past 20 days is -4.74% for TCRX’s stock, with a 57.04% simple moving average for the past 200 days.
Is It Worth Investing in Tscan Therapeutics Inc (NASDAQ: TCRX) Right Now?
Additionally, the 36-month beta value for TCRX is 0.94. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for TCRX is 36.46M and currently, short sellers hold a 0.60% ratio of that float. The average trading volume of TCRX on April 17, 2024 was 163.50K shares.
TCRX) stock’s latest price update
Tscan Therapeutics Inc (NASDAQ: TCRX) has experienced a rise in its stock price by 0.28 compared to its previous closing price of 7.13. However, the company has seen a fall of -1.11% in its stock price over the last five trading days. InvestorPlace reported 2024-03-17 that Generally speaking, you want to minimize your exposure to cheap stocks under $10. Yes, smaller companies have the potential to rise dramatically higher than their larger counterparts.
Analysts’ Opinion of TCRX
Many brokerage firms have already submitted their reports for TCRX stocks, with Wedbush repeating the rating for TCRX by listing it as a “Outperform.” The predicted price for TCRX in the upcoming period, according to Wedbush is $8 based on the research report published on June 22, 2023 of the previous year 2023.
TCRX Trading at 3.09% from the 50-Day Moving Average
After a stumble in the market that brought TCRX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -20.56% of loss for the given period.
Volatility was left at 7.43%, however, over the last 30 days, the volatility rate increased by 6.98%, as shares surge +2.80% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +29.10% upper at present.
During the last 5 trading sessions, TCRX fell by -0.90%, which changed the moving average for the period of 200-days by +186.60% in comparison to the 20-day moving average, which settled at $7.52. In addition, Tscan Therapeutics Inc saw 22.64% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at TCRX starting from BARBERICH TIMOTHY J, who purchase 317 shares at the price of $4.97 back on Dec 19 ’23. After this action, BARBERICH TIMOTHY J now owns 67,027 shares of Tscan Therapeutics Inc, valued at $1,575 using the latest closing price.
BARBERICH TIMOTHY J, the Director of Tscan Therapeutics Inc, purchase 28,830 shares at $4.89 during a trade that took place back on Dec 18 ’23, which means that BARBERICH TIMOTHY J is holding 66,710 shares at $140,881 based on the most recent closing price.
Stock Fundamentals for TCRX
Current profitability levels for the company are sitting at:
- -4.44 for the present operating margin
- 0.75 for the gross margin
The net margin for Tscan Therapeutics Inc stands at -4.28. The total capital return value is set at -0.39. Equity return is now at value -71.29, with -37.87 for asset returns.
Based on Tscan Therapeutics Inc (TCRX), the company’s capital structure generated 0.18 points at debt to capital in total, while cash flow to debt ratio is standing at -1.84. The debt to equity ratio resting at 0.22. The interest coverage ratio of the stock is -52.07.
Currently, EBITDA for the company is -88.1 million with net debt to EBITDA at 0.46. When we switch over and look at the enterprise to sales, we see a ratio of 12.93. The liquidity ratio also appears to be rather interesting for investors as it stands at 6.51.
Conclusion
In conclusion, Tscan Therapeutics Inc (TCRX) has seen better performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
